vs
Side-by-side financial comparison of Atara Biotherapeutics, Inc. (ATRA) and PureCycle Technologies, Inc. (PCT). Click either name above to swap in a different company.
PureCycle Technologies, Inc. is the larger business by last-quarter revenue ($2.7M vs $1.6M, roughly 1.7× Atara Biotherapeutics, Inc.).
Atara Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic T-cell immunotherapies for patients with unmet medical needs across oncology, autoimmune disease, and infectious disease indications. It operates primarily in North America, Europe, and Asia-Pacific, partnering with research institutions to advance its novel treatment pipeline.
PureCycle Technologies, Inc. is a sustainable materials firm with proprietary advanced polypropylene recycling technology. It converts contaminated polypropylene waste into high-purity virgin-equivalent resin for use in consumer goods, automotive parts, packaging and industrial products, serving global partners.
ATRA vs PCT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.6M | $2.7M |
| Net Profit | — | $-18.8M |
| Gross Margin | — | — |
| Operating Margin | — | -2196.1% |
| Net Margin | — | -697.1% |
| Revenue YoY | -95.1% | — |
| Net Profit YoY | 73.2% | 71.0% |
| EPS (diluted) | — | $-0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6M | $2.7M | ||
| Q3 25 | $3.5M | $2.4M | ||
| Q2 25 | $17.6M | $1.6M | ||
| Q1 25 | $98.1M | $1.6M | ||
| Q4 24 | $32.8M | $0 | ||
| Q3 24 | $40.2M | $0 | ||
| Q2 24 | $28.6M | $0 | ||
| Q1 24 | $27.4M | $0 |
| Q4 25 | — | $-18.8M | ||
| Q3 25 | $-4.3M | $-28.4M | ||
| Q2 25 | $2.4M | $-144.2M | ||
| Q1 25 | $38.0M | $8.8M | ||
| Q4 24 | $-12.7M | $-64.7M | ||
| Q3 24 | $-21.9M | $-90.6M | ||
| Q2 24 | $-19.0M | $-48.2M | ||
| Q1 24 | $-31.8M | $-85.6M |
| Q4 25 | — | -2196.1% | ||
| Q3 25 | -103.5% | -1602.2% | ||
| Q2 25 | 18.2% | -2763.5% | ||
| Q1 25 | 39.5% | -2387.4% | ||
| Q4 24 | -37.3% | — | ||
| Q3 24 | -54.1% | — | ||
| Q2 24 | -63.7% | — | ||
| Q1 24 | -114.2% | — |
| Q4 25 | — | -697.1% | ||
| Q3 25 | -124.6% | -1167.5% | ||
| Q2 25 | 13.6% | -8741.8% | ||
| Q1 25 | 38.7% | 559.0% | ||
| Q4 24 | -38.8% | — | ||
| Q3 24 | -54.5% | — | ||
| Q2 24 | -66.5% | — | ||
| Q1 24 | -116.1% | — |
| Q4 25 | — | $-0.14 | ||
| Q3 25 | $-0.32 | $-0.31 | ||
| Q2 25 | $0.19 | $-0.81 | ||
| Q1 25 | $3.50 | $0.05 | ||
| Q4 24 | $0.27 | $-0.40 | ||
| Q3 24 | $-2.93 | $-0.54 | ||
| Q2 24 | $-3.10 | $-0.29 | ||
| Q1 24 | $-5.65 | $-0.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $156.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-38.5M | $45.9M |
| Total Assets | $20.2M | $922.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $156.7M | ||
| Q3 25 | $13.7M | $234.4M | ||
| Q2 25 | $22.3M | $284.1M | ||
| Q1 25 | $13.8M | $22.5M | ||
| Q4 24 | $42.5M | $15.7M | ||
| Q3 24 | $67.2M | $83.7M | ||
| Q2 24 | $35.3M | $10.9M | ||
| Q1 24 | $46.2M | $25.0M |
| Q4 25 | $-38.5M | $45.9M | ||
| Q3 25 | $-36.6M | $68.2M | ||
| Q2 25 | $-35.0M | $98.9M | ||
| Q1 25 | $-55.1M | $238.2M | ||
| Q4 24 | $-97.3M | $180.4M | ||
| Q3 24 | $-90.5M | $241.4M | ||
| Q2 24 | $-110.9M | $291.6M | ||
| Q1 24 | $-98.3M | $336.8M |
| Q4 25 | $20.2M | $922.7M | ||
| Q3 25 | $30.2M | $989.1M | ||
| Q2 25 | $36.9M | $1.0B | ||
| Q1 25 | $62.0M | $787.3M | ||
| Q4 24 | $109.1M | $798.4M | ||
| Q3 24 | $142.7M | $788.8M | ||
| Q2 24 | $117.3M | $719.8M | ||
| Q1 24 | $165.3M | $734.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-50.9M | $-28.7M |
| Free Cash FlowOCF − Capex | — | $-42.0M |
| FCF MarginFCF / Revenue | — | -1559.6% |
| Capex IntensityCapex / Revenue | 0.0% | 495.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-183.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-50.9M | $-28.7M | ||
| Q3 25 | $-9.8M | $-38.5M | ||
| Q2 25 | $-7.3M | $-36.7M | ||
| Q1 25 | $-28.1M | $-38.9M | ||
| Q4 24 | $-24.5M | $-31.8M | ||
| Q3 24 | $-4.0M | $-33.4M | ||
| Q2 24 | $-10.6M | $-40.4M | ||
| Q1 24 | $-29.6M | $-39.2M |
| Q4 25 | — | $-42.0M | ||
| Q3 25 | — | $-42.4M | ||
| Q2 25 | — | $-45.3M | ||
| Q1 25 | — | $-53.9M | ||
| Q4 24 | $-24.6M | $-53.4M | ||
| Q3 24 | — | $-42.6M | ||
| Q2 24 | $-10.7M | $-50.8M | ||
| Q1 24 | $-29.7M | $-53.5M |
| Q4 25 | — | -1559.6% | ||
| Q3 25 | — | -1743.1% | ||
| Q2 25 | — | -2747.1% | ||
| Q1 25 | — | -3409.6% | ||
| Q4 24 | -75.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -37.3% | — | ||
| Q1 24 | -108.7% | — |
| Q4 25 | 0.0% | 495.1% | ||
| Q3 25 | 0.0% | 160.3% | ||
| Q2 25 | 0.0% | 521.5% | ||
| Q1 25 | 0.0% | 949.6% | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -3.07× | — | ||
| Q1 25 | -0.74× | -4.40× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
